View More Recent Stories

Sep 29, 2021 07:00AM Data Presented at IDWeek™ 2021 Demonstrate that ALVR109, AlloVir’s Investigational SARS-CoV-2-Specific T Cell Therapy, Is Reactive Against a Broad Range of Variants, Including Delta
Sep 7, 2021 07:00AM AlloVir to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
View More Recent Stories